AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Transplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell TransplantationMyeloablative AgonistsAntineoplastic Combined Chemotherapy ProtocolsMelphalanCombined Modality TherapyBone Marrow TransplantationThiotepaTransplantation ConditioningPeripheral Blood Stem Cell TransplantationTransplantation, HomologousMultiple MyelomaBone MarrowEtoposideTreatment OutcomeBone Marrow CellsRemission InductionCyclophosphamideDisease-Free SurvivalSalvage TherapyStem CellsGraft vs Host DiseaseLymphoma, Non-HodgkinHodgkin DiseaseRecurrenceBone Marrow PurgingCytarabineWhole-Body IrradiationSurvival RateHematopoietic Stem Cell MobilizationHematologic NeoplasmsCarmustineHematopoietic Stem CellsSurvival AnalysisBusulfanCarboplatinVincristineDoxorubicinNeuroblastomaPrognosisRetrospective StudiesGraft SurvivalLymphoma, Mantle-CellAntineoplastic AgentsAntigens, CD34Follow-Up StudiesDexamethasoneAmyloidosisBone and BonesTime FactorsAntineoplastic Agents, AlkylatingGranulocyte Colony-Stimulating FactorLymphoma, FollicularBoronic AcidsPyrazinesChemotherapy, AdjuvantAntibodies, Monoclonal, Murine-DerivedTransplantation ChimeraCord Blood Stem Cell TransplantationIfosfamideLymphoma, T-Cell, PeripheralLymphomaLeukemia, Myeloid, AcuteLeukapheresisInduction ChemotherapyAutograftsThalidomideLiver TransplantationMesenchymal Stem Cell TransplantationNeoplasm, ResidualTissue DonorsPrednisoneMyelodysplastic SyndromesCisplatinPodophyllotoxinHematopoiesisLymphoma, Large B-Cell, DiffuseHistocompatibility TestingMaintenance ChemotherapyLeukemiaBone Marrow DiseasesCell DifferentiationProspective StudiesAntibodies, MonoclonalDrug Administration ScheduleIdarubicinImmunosuppressive AgentsCell TransplantationLeukemia, MyeloidNeoplasm Recurrence, LocalBlood Component RemovalLymphoma, B-CellMitoxantroneRadioimmunotherapyHistocompatibilityKidney TransplantationNeoplasms, Second PrimaryVidarabineAcute Disease
Destroyed tissue anTransplantHSCTGraft-versus-LymphomaPatient's own stem cellsMultiple myelomaTransplantsAllogeneic hematopoietic stem cDonorsAcuteRegimensMultipotent hematopoietic stemTherapyUmbilicalWorld Marrow Donor AssociationMalignancyMalignantConditioning for allogeneicEngraftmentApheresisRelapseComplete remissionAllogenicCord-bloodImmuneDonorLymphomasClinicalEtoposideImmunosuppressionProgenitor cellCytotoxic chemotherapyCyclophosphamideAplastic anemiaLymphocytesSurvivalRadiotherapySolid tumorsAutoHCTMetastasesImmunotherapyTumorNeuroblastomaPBSCTPost-transplantationDisordersBlood stem-cellRefractoryEfficacy
Destroyed tissue an1
  • The patient's own stored stem cells are then transfused into his/her bloodstream, where they replace destroyed tissue and resume the patient's normal blood-cell production. (wikipedia.org)
Transplant51
  • Non-myeloablative, so-called mini transplant (microtransplantation) procedures, have been developed requiring smaller doses of preparative chemotherapy and radiation therapy, allowing HSCT to be conducted in the elderly and other patients who would otherwise be considered too weak to withstand a conventional treatment regimen. (wikipedia.org)
  • The Worldwide Network for Blood and Marrow Transplantation reported the millionth transplant to have been undertaken in December 2012. (wikipedia.org)
  • Cells for HSCT may be obtained from the patient himself or herself (autologous transplant) or from another person, such as a sibling or unrelated donor (allogeneic transplant) or an identical twin (syngeneic transplant). (medscape.com)
  • At times, very advanced and nonresponsive lymphomas may be treated using a bone marrow transplant (marrow is the soft tissue in the centre of large bones that produces white and red blood cells and platelets) or stem-cell transplantation (the cells that develop blood). (lymphoma.ca)
  • A syngeneic transplant is when the cells are donated by an identical twin. (lymphoma.ca)
  • To combat this problem, the patient receives a bone marrow or a stem-cell transplant. (lymphoma.ca)
  • What is the Difference Between a Bone Marrow Transplant and a Stem-cell Transplant? (lymphoma.ca)
  • Harvesting is the procedure by which the bone marrow or stem cells are obtained in preparation for the transplant. (lymphoma.ca)
  • In a bone marrow transplant, the stem cells are withdrawn from the bone marrow under general anesthesia by inserting a needle into a bone in the pelvic region, called the iliac crest. (lymphoma.ca)
  • This bone marrow is then filtered and stored until the day of the transplant. (lymphoma.ca)
  • Stem cells or bone marrow harvested from the patient (autologous transplant) are generally preserved and stored in a freezer until ready for use. (lymphoma.ca)
  • Stem cells or bone marrow derived from a donor (allogeneic transplant) are usually collected immediately before use and not stored for any length of time. (lymphoma.ca)
  • Transplant Cell Ther 2021. (harvard.edu)
  • Defibrotide: Real World Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Stem Cell Transplant. (harvard.edu)
  • Adding venetoclax to fludarabine/busulfan RIC transplant for high risk MDS and AML is feasible, safe, and active. (harvard.edu)
  • In the mid-20th century, Dr. E. Donnall Thomas achieved a landmark breakthrough by successfully performing the first bone marrow transplant between identical twins in 1956 (Thomas et al. (revistadehematologia.org.mx)
  • In April 1960, Dr. Álvaro Gómez-Leal, presented during the first meeting of the Agrupación Mexicana para el Estudio de la Hematología, A.C., data on a transplant of allogeneic stem cells in a patient with acute leukemia done in Monterrey, Mexico: the patient received high-dose chemotherapy followed by stem cells from the bone marrow of his brother, improving and obtaining remission for months but relapsing and subsequently died. (revistadehematologia.org.mx)
  • It was only until 1988 when the same group could report on their first successful bone marrow transplant (León-Rodríguez et al. (revistadehematologia.org.mx)
  • Such resources can be created by blood and marrow transplantation societies and patient advocacy groups, ideally in collaboration with MM specialists at transplant centers. (bvsalud.org)
  • Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. (uchicago.edu)
  • Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. (uchicago.edu)
  • Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. (uchicago.edu)
  • Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. (uchicago.edu)
  • Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. (uchicago.edu)
  • Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. (uchicago.edu)
  • Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. (uchicago.edu)
  • T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. (uchicago.edu)
  • Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. (uchicago.edu)
  • Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. (uchicago.edu)
  • At 4 years of age and 29 months post-transplant, the patient demonstrated normal T-lymphocyte and natural killer cell numbers. (frontiersin.org)
  • In this month's Pharmacy SIG Literature Update: Impact of anti-T-lymphocyte globulin dosing on GVHD in MUD SCT, impact of MRD status before alloHCT on outcomes in secondary AML, low-dose post- transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of GVHD in MUD SCT and more. (astct.org)
  • Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma. (astct.org)
  • Allogeneic HCT has been widely used, while autologous HCT, which is still useful, is less prevalent because of concerns around post-transplant relapse, as well as the recently extended application of allogeneic HCT. (apbmt.org)
  • Blood and Marrow Transplant Research [CIBMTR] in 2004), the European Research Project on Cord Blood Transplantation (Eurocord) in 1993, and the Japanese Cord Blood Banking Network in 1996-expedited the clinical evaluation of the efficacy and safety of transplantation of cord blood from unrelated donors. (nationalacademies.org)
  • When considering a bone marrow transplant in Durban, exploring different hospitals and doctors to find the right treatment and care for your specific needs is important. (yapitahealth.com)
  • What is a bone marrow transplant? (yapitahealth.com)
  • In bone marrow transplant or stem cell transplant, healthy blood-forming stem cells replace damaged bone marrow that cannot produce enough healthy blood cells. (yapitahealth.com)
  • Why would someone need to have a bone marrow transplant? (yapitahealth.com)
  • Bone marrow transplant is recommended when bone marrow lacks stem cell production. (yapitahealth.com)
  • What conditions can a bone marrow transplant treat? (yapitahealth.com)
  • Patients are explained thoroughly regarding Bone marrow transplant including the evaluation process, treatment side effects, cost of treatment, and associated complications. (yapitahealth.com)
  • Finding accommodation in a hotel because patients for autologous transplants need to stay for 30 days locally and allogenic transplant patients need to stay for 100 days. (yapitahealth.com)
  • Mini transplant or reduced-intensity therapy means chemotherapy and radiation in smaller doses while myeloablative or ablative therapy means high doses of radiation, chemotherapy, or combination. (yapitahealth.com)
  • In autologous transplant- the patient's own stem cells are collected and stored before conditioning. (yapitahealth.com)
  • The purpose of this study is to assess the effect your disease and the treatment of allogeneic stem cell transplant has upon you before and after your treatment process through questionnaires at certain time points. (mayo.edu)
  • The primary purpose of this study is to demonstrate the feasibility of sublingual (SL) administration of tacrolimus in blood and marrow transplant (BMT) patients. (mayo.edu)
  • The aim of this study is to measure the differences in quality of life and mood of hematopoietic stem cell transplant (HCT) patients and their caregivers staying at a hospital hospitality house (HHH), such as the Gift of Life Transplant House, the Help in Healing Home, and the Gabriel House of Care versus staying at a hotel/rental apartment or house. (mayo.edu)
  • Professor Ma holds leadership or scientific membership positions in a number of national and international scientific communities including the World Network for Blood & Marrow Transplantation (a WHO affiliated NGO), the AsiaPacific BM Transplant and the Royal College of Pathology of Australasian Quality Assurance Programme. (edu.au)
  • Dr. Dora Ho specializes in infection complications in immunocompromised patients, such as those with bone marrow transplant, solid organ transplant, cancers and other forms of immunodeficiency. (stanford.edu)
  • Aim: To report our experience with ALOHT in acute myelogenous leukemia (AML), analyzing patient age at transplantation in different periods and transplant results in different age groups. (scielo.org)
HSCT24
  • Body iron disorders have been reported after myeloablative conditioning in patients undergoing hematopoietic stem cell transplantation (HSCT). (karger.com)
  • Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood in order to replicate inside of a patient and to produce additional normal blood cells. (wikipedia.org)
  • Autologous HSCT requires the extraction (apheresis) of hematopoietic stem cells (HSCs) from the patient and storage of the harvested cells in a freezer. (wikipedia.org)
  • These advantages have established autologous HSCT as one of the standard second-line treatments for such diseases as lymphoma. (wikipedia.org)
  • Hematopoietic stem cell transplantation (HSCT) involves the intravenous infusion of hematopoietic stem cells in order to reestablish blood cell production in patients whose bone marrow or immune system is damaged or defective. (medscape.com)
  • The National Marrow Donor Program (NMDP), founded in 1986, and the World Marrow Donor Association (WMDA), founded in 1988, were established to (1) locate and secure appropriate unrelated-donor HSCT sources for patients by promoting volunteer donation of bone marrow and peripheral blood stem cells in the community and (2) promote ethical practices of sharing stem cell sources by need, rather than by geographic location of the donor. (medscape.com)
  • This, along with the development of unrelated cord blood transplantation and familial haploidentical transplantation methods, have improved the likelihood of finding an appropriate HSCT source in a timely manner. (medscape.com)
  • This was the first report of a hematopoietic stem cell transplantation (HSCT) conducted in Mexico, only 4 years after the pioneer work by E. Donnall Thomas in Cooperstown, New York, USA (Ruiz-Argüelles et al. (revistadehematologia.org.mx)
  • Given the potential importance of MAIT cells in control of microbial infections and protection of epithelial surfaces, we investigated MAIT cell reconstitution in 43 children who underwent hematopoietic stem cell transplantation (HSCT) after myeloablative conditioning for the treatment of malignant hematological disease. (cryostem.org)
  • The purpose of this study is to measure the effect of Hematopoietic Stem Cell Transplantation (HSCT) on symptoms of CSF1R-related Leukoencephalopathy. (mayo.edu)
  • His research focus is on haematopoietic stem cell transplantation (HSCT) and translational research of normal and malignant stem cells. (edu.au)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) offers a curative treatment for acute myeloid leukemia patients. (oncotarget.com)
  • However, disease recurrence remains a major clinical challenge and identification of high-risk patients prior to HSCT is crucial to improve outcomes. (oncotarget.com)
  • We performed absolute quantification of BAALC copy numbers in peripheral blood prior (median 7 days) to HSCT in complete remission (CR) or CR with incomplete peripheral recovery in 82 acute myeloid leukemia patients using digital droplet PCR (ddPCR) technology. (oncotarget.com)
  • High pre-HSCT BAALC / ABL1 copy numbers significantly associated with higher cumulative incidence of relapse and shorter overall survival in univariable and multivariable models. (oncotarget.com)
  • Patients with high pre-HSCT BAALC / ABL1 copy numbers were more likely to experience relapse within 100 days after HSCT. (oncotarget.com)
  • Evaluation of pre-HSCT BAALC / ABL1 copy numbers in peripheral blood by ddPCR represents a feasible and rapid way to identify acute myeloid leukemia patients at high risk of early relapse after HSCT. (oncotarget.com)
  • In the future, prospective studies should evaluate whether acute myeloid leukemia patients with high pre-HSCT BAALC / ABL1 copy numbers benefit from additional treatment before or early intervention after HSCT. (oncotarget.com)
  • This is a phase I/II clinical trial to determine the maximum tolerated dose (MTD) of total marrow irradiation (TMI) followed by fludarabine in the context of a myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT), as well as to determine the efficacy of the regimen in patients with high-risk leukemia and myelodysplasia. (sparkcures.com)
  • The Hematopoietic stem cell transplantation (HSCT) is used in children as a definitive treatment for various oncological, immune deficiencies, hemoglobinopathy, and malignancies diseases that involve the hematological system, congenital metabolism disorders, among others. (bvsalud.org)
  • This is a quantitative, retrospective, observational, descriptive and analytical quantitative approach approaching the medical records of children and adolescents submitted to HSCT in a referral hospital service for this type of transplantation in the state of Rio Grande do Sul North (RN). (bvsalud.org)
  • The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
  • The profile of the clinical variables presented by the children and adolescents of this study shows that the most prevalent diagnosis was ALL, the most frequent toxicities were gastrointestinal, cardiac, respiratory and hematological, the most common HSCT was allogeneic peripheral blood and the greatest cause of mortality was sepsis. (bvsalud.org)
  • Hematopoietic stem cell transplantation not responded to other therapeutic modalities, with (HSCT) is used in children as a definitive treatment an increase in survival after transplantation, for different oncological, immune deficiencies, contributing to its use (YEILIPEK, 2014). (bvsalud.org)
Graft-versus-5
  • We aimed to identify the risk factors that predict transplantation outcomes in patients with MF who underwent matched or mismatched allo-SCT using a uniform myeloablative conditioning regimen consisting of busulfan and fludarabine with tacrolimus and methotrexate-based graft-versus-host disease prophylaxis. (bvsalud.org)
  • Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. (uchicago.edu)
  • The use of allogeneic hematopoietic cell transplantation (HCT) is the most potent immunotherapeutic treatment for hematologic diseases, but its practical use is impeded by acute and chronic graft-versus-host disease (GvHD). (cryostem.org)
  • Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation. (kyoto-u.ac.jp)
  • Abstract Introduction: Graft-versus-host disease (GVHD) is a serious complication in allogeneic transplantation. (scielo.org)
Lymphoma18
  • Other conditions treated with stem cell transplants include sickle cell disease, myelodysplastic syndrome, neuroblastoma, lymphoma, Ewing's sarcoma, desmoplastic small round cell tumor, chronic granulomatous disease, Hodgkin's disease and Wiskott-Aldrich syndrome. (wikipedia.org)
  • [ 1 ] More than half of autologous transplantations are performed for multiple myeloma and non-Hodgkin lymphoma , and the vast majority of allogeneic transplants are performed for hematologic and lymphoid cancers. (medscape.com)
  • Therefore, the doses of chemotherapy and radiation therapy used to treat lymphoma are limited due to the risk of damaging these stem cells. (lymphoma.ca)
  • Although children, adolescents, and young adults with newly diagnosed B-cell non-Hodgkin's lymphoma enjoy excellent overall survival with current chemoimmunotherapy, those with relapsed and/or refractory disease have a dismal prognosis. (jnccn.org)
  • Children, adolescents, and young adults (CAYAs) with newly diagnosed B-cell non-Hodgkin's lymphoma (B-NHL) enjoy excellent overall survival (OS) with current frontline chemoimmunotherapy. (jnccn.org)
  • Kaplan-Meier curve showing probability of overall survival in children and adolescents with mature B-cell non‐Hodgkin's lymphoma with refractory or relapsed disease during or after therapy in the FAB/LMB96 international study. (jnccn.org)
  • Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group. (jnccn.org)
  • Lymphoma is the most common haematopoietic malignancy in dogs, and is the most responsive to chemotherapy. (vin.com)
  • The most common physical finding in dogs with lymphoma is peripheral lymphadenopathy, which is usually generalized but may be localized to a single lymph node or a region of the body. (vin.com)
  • Overall, COP chemotherapy causes complete remission in about 70% of dogs with lymphoma for a median of 130 days. (vin.com)
  • Bone marrow transplantation is a complex yet life-saving procedure that can benefit individuals with a wide range of diseases, including blood cancers like leukemia and lymphoma, aplastic anemia, immune deficiencies, and genetic disorders. (yapitahealth.com)
  • Adult T-cell leukemia/lymphoma (ATLL) is a rare and aggressive disease caused by human T-cell lymphotropic virus type 1 that predominantly affects Japanese and Caribbean populations. (oncotarget.com)
  • Adult T-cell leukemia/lymphoma (ATLL) is a rare mature T-cell malignancy first described in Japan in 1977 [ 1 ]. (oncotarget.com)
  • Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. (ucsf.edu)
  • Geriatric assessment in adults age 50 years and older undergoing autologous hematopoietic cell transplantation for lymphoma. (ucsf.edu)
  • FDA granted accelerated approval to glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. (org.in)
  • FDA granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. (org.in)
  • FDA approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.) with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. (org.in)
Patient's own stem cells2
Multiple myeloma9
  • It is most often performed for patients with certain cancers of the blood or bone marrow, such as multiple myeloma or leukemia. (wikipedia.org)
  • Several studies are evaluating the role of treatment in patients with high-risk smoldering multiple myeloma (SMM). (medscape.com)
  • Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. (shengsci.com)
  • Eighty-two patients with advanced multiple myeloma (MM) were enrolled in 2 sequential clinical studies of 1 or 2 courses of myeloablative therapy with stem cell support. (shengsci.com)
  • Multiple myeloma is a cancer of plasma cells that produce monoclonal immunoglobulin and invade and destroy adjacent bone tissue. (merckmanuals.com)
  • Multiple myeloma (MM) patients with high-risk cytogenetic abnormalities have inferior survival outcomes and are underrepresented in clinical trials. (bvsalud.org)
  • Autologous stem cell transplantation (ASCT) is a standard of care treatment for patients with multiple myeloma (MM). However, only 20% to 30% of patients with MM for whom the procedure is indicated undergo ASCT. (bvsalud.org)
  • Multiple myeloma is a bone marrow disease characterized by the presence of malignant plasma cells, & abnormal serum &/or urine immunoglobulin secondary to clonal plasma cell expansion. (mims.com)
  • FDA granted accelerated approval to elranatamab-bcmm (Elrexfio, Pfizer, Inc.), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (org.in)
Transplants8
  • Autologous transplants have the advantage of lower risk of infection during the immune-compromised portion of the treatment, since the recovery of immune function is rapid. (wikipedia.org)
  • How do Stem-cell Transplants Work? (lymphoma.ca)
  • There are two different types of transplants: bone marrow transplants and peripheral blood stem-cell transplants (PBSCTs). (lymphoma.ca)
  • In bone marrow transplants, the stem cells are taken from the bone marrow. (lymphoma.ca)
  • PBSCTs are now more commonly performed than bone marrow transplants, as the procedure is easier and the body is able to regenerate new stem cells faster. (lymphoma.ca)
  • At the time they performed the first transplants surprisingly little was known about hematopoietic stem cells, immune responses to transplants or the complex human leucocyte antigen system. (revistadehematologia.org.mx)
  • BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. (uchicago.edu)
  • Overall, Durban offers a range of specialized hospitals and experienced medical professionals for bone marrow transplants, making it a viable option for individuals seeking this procedure. (yapitahealth.com)
Allogeneic hematopoietic stem c2
  • Allogeneic hematopoietic stem cell transplantation is limited mainly by lack of histocompatible donors. (msdmanuals.com)
  • National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. (uchicago.edu)
Donors5
Acute14
  • Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. (shengsci.com)
  • Previous studies have shown that children with acute myeloid leukemia (AML) who developed mixed chimerism (MC) were at high risk for relapse after allogeneic stem-cell transplantation (allo-SCT). (shengsci.com)
  • I have expertise in novel therapies for acute myeloid leukemia, stem cell mobilization and homing, as well as stem cell transplantation. (rochester.edu)
  • This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). (rochester.edu)
  • Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. (uchicago.edu)
  • Hematopoietic cell transplantation (HCT) is an integral part of the treatment of acute myeloid leukemia (AML). (apbmt.org)
  • Hematopoietic cell transplantation (HCT) is an effective treatment in patients with acute myeloid leukemia (AML). (apbmt.org)
  • ATLL in the Caribbean population presents more often as the acute and lymphomatous subtypes, is associated with complex cytogenetics, and has a high rate of CNS involvement. (oncotarget.com)
  • High risk of acute pulmonary toxicity with both myeloablative and non-myeloablative total body irradiation-based conditioning for allogeneic stem cell transplantation. (dukecancerinstitute.org)
  • Following induction and consolidation treatment for acute myeloid leukaemia the duration of treatment may be substantially longer (up to 38 days) depending on the type, dose and schedule of cytotoxic chemotherapy used. (medicines.org.uk)
  • Manufacturing results of tisagenlecleucel for acute lymphoblastic leukemia: a survey by the CAR-T cell therapy taskforce of the Japan Society of Transfusion Medicine and Cell Therapy]. (kyoto-u.ac.jp)
  • High BAALC expression levels at acute myeloid leukemia diagnosis have been linked to adverse outcomes. (oncotarget.com)
  • Recent data indicate that high BAALC expression levels may also be used as marker for residual disease following acute myeloid leukemia treatment. (oncotarget.com)
  • FDA approved quizartinib (Vanflyta, Daiichi Sankyo, Inc.) with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. (org.in)
Regimens5
  • Conditioning regimens consisted of high-dose melphalan (MEL) with or without total body irradiation (TX1 = 35) and MEL as the first preparative regim. (shengsci.com)
  • Outcomes of myelofibrosis (MF) with allogeneic stem cell transplantation (allo-SCT) have improved over the past decade, related in part to advances in supportive treatments and conditioning regimens. (bvsalud.org)
  • However, most studies lack homogeneity in conditioning regimens used, limiting their ability to assess prognostic factors on transplantation outcomes. (bvsalud.org)
  • All chemotherapy regimens require that the recipient be capable of undergoing the treatment. (worldsbest.rehab)
  • Current chemotherapy regimens apply drug treatment in cycles, with the frequency and duration of treatments limited by toxicity. (worldsbest.rehab)
Multipotent hematopoietic stem1
Therapy29
  • Iodine-131-metaiodiobenzylguanidine ( 131 I-MIBG) therapy combined with allogeneic cord blood stem cell transplantation (SCT) was used to treat a 4-year-old girl with recurrent neuroblastoma. (biomedcentral.com)
  • Based on our findings, we suggest that 131 I-MIBG treatment with myeloablative allogeneic SCT should be considered as first-line therapy for high-risk neuroblastoma patients when possible. (biomedcentral.com)
  • After therapy, the frozen marrow or cells are thawed and put back in the body. (lymphoma.ca)
  • Stem cells, because they divide rapidly, can be killed off by chemotherapy and radiation therapy. (lymphoma.ca)
  • Patients with lymphomas that are difficult to treat or resistant to standard therapy may benefit from chemotherapy or radiation therapy given in very high doses (myeloablative therapy). (lymphoma.ca)
  • This means that they receive stem cells (either their own stem cells that were stored prior to myeloablative therapy or stem cells from a donor) to replenish their bone marrow which had previously been destroyed by the high-dose therapy. (lymphoma.ca)
  • High-dose chemotherapy, with or without myeloablative radiation therapy, is then administered to the patient to destroy the cancerous cells, as well as the healthy cells in the bone marrow. (lymphoma.ca)
  • Unituxin is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. (nih.gov)
  • Bone Marrow Suppression: Monitor peripheral blood counts during Unituxin therapy. (nih.gov)
  • Although most clinicians would agree that hematopoietic progenitor cell transplantation after reinduction therapy is frontline therapy for these patients, there is no consensus as to what type of hematopoietic progenitor cell transplantation promises the best event-free and overall survival. (jnccn.org)
  • This review outlines the disparate types of stem cell therapy that have been used in this difficult-to-treat population as well as the role of maintenance and CAR T-cell therapy in conjunction with stem cell therapy. (jnccn.org)
  • 1 - 3 However, those with relapsed and/or refractory (R/R) disease have had a historically dismal OS of ≤30% despite reinduction therapy and autologous hematopoietic progenitor cell transplantation (autoHCT) ( Figure 1 ). (jnccn.org)
  • HCT, whether it be autologous, allogeneic, or tandem, has been and continues to be an integral part of therapy, with varying outcomes as delineated in Table 2 . (jnccn.org)
  • and the role of CAR T-cell therapy as it relates to HCT as therapies for R/R B-NHL. (jnccn.org)
  • In Section II, Dr. James Griffin reviews the mechanisms that lead to activation of tyrosine kinases by mutations in AML, the consequences of that activation for the cell, and the opportunities for targeted therapy and discusses some examples of developing novel drugs (tyrosine kinase inhibitors) and their effectiveness in AML (FLT3). (ashpublications.org)
  • Fifty-six patients (71%) received post-transplantation maintenance therapy. (bvsalud.org)
  • Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. (uchicago.edu)
  • mobilization of peripheral blood stem cells, including after myelosuppressive therapy. (ru-pills.com)
  • The only curative therapy is hematopoietic stem cell transplantation. (frontiersin.org)
  • 0.5 x 109 cells/kg and being transplanted in CR1 versus CR/PR from second-line therapy were identified as independent predictors for OS and PFS. (astct.org)
  • In a combined analysis of categorical groups, the patients in the high A- ALC group transplanted in CR1 had the best prognosis for OS and PFS and patients in the low A- ALC group transplanted in CR/PR after second-line therapy had the worse prognosis for OS and PFS. (astct.org)
  • Prognostic factors include stage and substage of disease, histologic type, immunophenotype (B-cell versus T-cell), presence of hypercalcemia, response to therapy, pre-treatment steroid therapy, and possibly gender. (vin.com)
  • Discovery and availability of biomarkers suitable for screening high risk patients using early, non-invasive, blood tests specific for GvHD-therapy resistance would significantly aid in the management of patients with this disease and would allow for rational drug development and drug approval by regulatory authorities. (cryostem.org)
  • This is the first analysis to describe ATLL pathological features, cytogenetics, and response to standard therapy and transplantation in the Caribbean cohort. (oncotarget.com)
  • Neupogen is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. (medicines.org.uk)
  • In patients receiving cytotoxic chemotherapy, a transient increase in neutrophil counts is typically seen 1 to 2 days after initiation of Neupogen therapy. (medicines.org.uk)
  • Transplantation and Cellular Therapy, Jul. (kyoto-u.ac.jp)
  • Transplantation and Cellular Therapy, Jun. (kyoto-u.ac.jp)
  • Importantly, the use of drugs (whether chemotherapy, hormonal therapy or targeted therapy) constitutes systemic therapy for cancer in that they are introduced into the blood stream and are therefore in principle able to address cancer at any anatomic location in the body. (worldsbest.rehab)
Umbilical5
World Marrow Donor Association1
  • In 2014, according to the World Marrow Donor Association, stem-cell products provided for unrelated transplantation worldwide had increased to 20,604 (4,149 bone-marrow donations, 12,506 peripheral blood stem-cell donations, and 3,949 cord-blood units). (wikipedia.org)
Malignancy1
  • The purpose is to deliver chemotherapy, immunotherapy, and/or radiation to eliminate malignancy, prevent rejection of new stem cells, and create space for the new cells. (medscape.com)
Malignant4
  • The patient is then treated with high-dose chemotherapy with or without radiotherapy with the intention of eradicating the patient's malignant cell population at the cost of partial or complete bone marrow ablation (destruction of patient's bone marrow's ability to grow new blood cells). (wikipedia.org)
  • Lesions are caused by bone replacement by expanding plasmacytomas or by cytokines that are secreted by malignant plasma cells that activate osteoclasts and suppress osteoblasts, leading to bone loss. (merckmanuals.com)
  • Giant cell tumor is a benign bone tumor, locally aggressive with low malignant potential. (jbstjournal.com)
  • A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. (curehunter.com)
Conditioning for allogeneic1
Engraftment2
  • However, HLA-identical sibling stem cell infusions in ADA-SCID result in some donor stem cell engraftment and long-term thymopoiesis. (frontiersin.org)
  • There was 93% donor T-lymphocytes, 20% donor B-lymphocytes, and 5% donor myeloid cells, indicative of some donor stem cell engraftment. (frontiersin.org)
Apheresis3
  • The stem cells are separated from other components of the blood in a process called apheresis, with the rest of the blood being returned to the patient. (lymphoma.ca)
  • Cell mobilization and apheresis procedures should be performed at an oncology or hematology center experienced in this field and the ability to adequately monitor hematopoietic progenitor cells. (ru-pills.com)
  • The mobilisation and apheresis procedures should be performed in collaboration with an oncology-haematology centre with acceptable experience in this field and where the monitoring of haematopoietic progenitor cells can be correctly performed. (medicines.org.uk)
Relapse3
  • The patient experienced relapse 2 years after receiving first-line therapies, which included chemotherapy, surgical resection, irradiation, and autologous peripheral SCT. (biomedcentral.com)
  • 1 , 2 , 4 - 6 Specifically, patients with lactate dehydrogenase ≥2 times the upper limit of normal (ULN) at diagnosis, R/R disease within 6 months of diagnosis, multisite relapse, and/or R/R disease with bone marrow involvement experience a significantly decreased OS ( Table 1 ). (jnccn.org)
  • Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
Complete remission1
  • Allogeneic transplantation was performed in five patients, two of whom achieved complete remission despite residual or refractory disease. (oncotarget.com)
Allogenic1
Cord-blood4
Immune8
  • In these cases, the recipient's immune system is usually destroyed with radiation or chemotherapy before the transplantation. (wikipedia.org)
  • Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. (shengsci.com)
  • 1957). This pioneering work laid the foundation for the exploration of hematopoietic stem cells and their role in treating diseases of the blood and immune system. (revistadehematologia.org.mx)
  • Myeloablative conditioning is recommended to prevent rejection caused by residual immune function. (frontiersin.org)
  • a broad range of disorders for which transplantion of HPCs from an adult donor is also successful, including hematological malignancies, solid tumors, constitutional and acquired bone marrow failure syndromes, hemoglobinopathies, congenital immune deficiencies, and inherited disorders of metabolism (Gluckman et al. (nationalacademies.org)
  • With damaged bone marrow, the body's immune system becomes weak and it increases the patient's risk of infections. (yapitahealth.com)
  • The conditioning method suppresses the immune system and destroys cancerous cells. (yapitahealth.com)
  • Because of the effect on immune cells (especially lymphocytes), chemotherapy drugs often find use in a host of diseases that result from harmful overactivity of the immune system against self (so-called autoimmunity). (worldsbest.rehab)
Donor8
  • Bone marrow or stem cells that have been removed from a donor are carefully frozen and stored while the patient receives high-dose chemotherapy and sometimes whole-body radiation treatment. (lymphoma.ca)
  • The harvested stem cells or bone marrow (obtained from either the patient's own healthy cells or from a donor) are then transplanted intravenously into the bloodstream of the patient. (lymphoma.ca)
  • Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. (harvard.edu)
  • eg, bone, bone marrow, and skin grafts) Genetically identical (syngeneic [between monozygotic twins]) donor tissue (isografts) Genetically. (msdmanuals.com)
  • Hematopoietic stem cell transplantation may be autologous (using the patient's own cells) or allogeneic (using cells from a donor). (msdmanuals.com)
  • Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation. (uchicago.edu)
  • She received a matched sibling donor unconditioned stem cell infusion at 16 months of age. (frontiersin.org)
  • Various factors including age, sex, performance status (PS), disease status, cytogenetic risk, donor type, graft source, sex mismatch between the donor and the recipient, and year of transplantation were all shown to impact OS 2 . (apbmt.org)
Lymphomas3
  • The National Cancer Institute's Working Formulation, originally proposed in 1982, classified and grouped lymphomas by morphology and clinical behavior (ie, low, intermediate, or high grade) with 10 subgroups labeled A to J. (medscape.com)
  • Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation. (astct.org)
  • Following established chemotherapy for solid tumours, lymphomas, and lymphoid leukaemia, it is expected that the duration of treatment required to fulfil these criteria will be up to 14 days. (medicines.org.uk)
Clinical9
  • Each of those cell sources has specific advantages and disadvantages, and each has found particular clinical applications. (medscape.com)
  • We have a series of clinical trials available to evaluate several different strategies to prevent GVHD, such as T cell depletion and the use of novel immunosuppressive agents. (harvard.edu)
  • In clinical studies of patients with high-risk neuroblastoma, Grade 3 peripheral sensory neuropathy occurred in 2% to 9% of patients. (nih.gov)
  • This is particularly apparent from the entree of high-throughput diagnostic technologies and the identification of prognostic and therapeutic targets, the introduction of therapies in genetically defined subgroups of AML, as well as the influx of investigational approaches and novel drugs into the pipeline of clinical trials that target pathogenetic mechanisms of the disease. (ashpublications.org)
  • Giant cell tumors (GCT) of the bone are aggressive and are recognised for variable clinical behaviour, which is not always related to radiographic or histological appearance [1]. (jbstjournal.com)
  • His pioneering work spans discoveries in basic biology of blood stem cells and leukemia to first-in-human clinical trials for people with cancer and heart diseases, alongside shaping innovative policies in state health and healthcare financing. (ufl.edu)
  • In randomised clinical trials, a subcutaneous dose of 230 µg/m 2 /day (4.0 to 8.4 µg/kg/day) was used. (medicines.org.uk)
  • Ma DD , 2007 , 'Expression of Neurofilament Proteins in Adult Bone Marrow Mesenchymal Stem Cells and Embryonic Stem Cells and Their Clinical Potential' , in Davenport LP (ed. (edu.au)
  • Treatment-related toxicity is frequently a dose-limiting factor and represents a major challenge in clinical management of cancer. (aspetjournals.org)
Etoposide2
Immunosuppression1
  • This results in the most common side-effects of chemotherapy: myelosuppression (decreased production of blood cells, hence also immunosuppression), mucositis (inflammation of the lining of the digestive tract), and alopecia (hair loss). (worldsbest.rehab)
Progenitor cell1
  • Enhancement of human erythroid progenitor cell growth by media conditioned by a human t-lymphocyte line. (shengsci.com)
Cytotoxic chemotherapy4
  • The safety and efficacy of administration of Neupogen® on the same day as myelosuppressive cytotoxic chemotherapy have not been established. (ru-pills.com)
  • Because of the sensitivity of rapidly dividing myeloid cells to myelosuppressive cytotoxic chemotherapy, administration of Neupogen® 24 hours before or after administration of these drugs is not recommended. (ru-pills.com)
  • The safety and efficacy of Neupogen are similar in adults and children receiving cytotoxic chemotherapy. (medicines.org.uk)
  • The first dose of Neupogen should be administered at least 24 hours after cytotoxic chemotherapy. (medicines.org.uk)
Cyclophosphamide1
Aplastic anemia1
  • Candidates for HSCTs include pediatric cases where the patient has an inborn defect such as severe combined immunodeficiency or congenital neutropenia with defective stem cells, and also children or adults with aplastic anemia who have lost their stem cells after birth. (wikipedia.org)
Lymphocytes4
  • Activation-induced cell death of human melanoma specific cytotoxic T lymphocytes is mediated by apoptosis-inducing factor. (uchc.edu)
  • Rescuing melanoma epitope-specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunotherapy. (uchc.edu)
  • Recent studies have shown that soluble factors elaborated by human T lymphocytes enhance erythroid burst formation by human peripheral blood null cells. (shengsci.com)
  • PNP is expressed at high levels in lymphocytes and causes the release of ribose phosphate by converting inosine to hypoxanthine, guanosine to guanine, and deoxyguanosine to guanine. (frontiersin.org)
Survival6
  • Median survival time from the institution of chemotherapy did not differ among the groups. (medscape.com)
  • The 30 patients who had no marrow metastases at the time of PSC harvesting had an actuarial event-free survival of 47%, while those 26 patients with marrow metastases had a significantly different actuarial event-free survival of 27% (P = .02). (shengsci.com)
  • CBV and PSCT for patients with relapsed Hodgkin's diseases who have marrow hypocellularity in traditional harvest sites or histopathologic evidence of BM metastases can result in long-term event-free survival. (shengsci.com)
  • There was no difference in survival between patients who received chemotherapy alone versus chemotherapy with antiviral agents. (oncotarget.com)
  • Recipients of allogeneic transplantation had significantly improved overall survival compared to non-transplanted patients. (oncotarget.com)
  • The median survival of patients treated with intensive chemotherapy aged less than 60 years and 60 years and above was 3.4 and 1 year, respectively. (scielo.org)
Radiotherapy3
  • Conditioning Process: Chemotherapy, radiotherapy or both are carried out before BMT to eliminate cancer or diseased cells. (yapitahealth.com)
  • Further, cancer treatment often involves radiotherapy and chemotherapy, which not only kills cancer cells but also affects healthy cells. (aspetjournals.org)
  • For instance, the use of 131 I radiotherapy to treat thyroid cancer is highly dependent on the selective expression of the sodium/iodine symporter on these cells ( Kogai and Brent, 2012 ). (aspetjournals.org)
Solid tumors1
AutoHCT3
  • There is scarce data on MM patients with more than one high-risk cytogenetic aberration (ie, ultra- high-risk MM). This study was conducted to evaluate outcomes of newly diagnosed MM patients with ultra-high-risk MM who underwent autologous hematopoietic stem cell transplantation (autoHCT). (bvsalud.org)
  • We conducted a retrospective single-center chart review analysis of adult patients with ultra-high-risk MM who underwent autoHCT between 2008 and 2018 at MD Anderson Cancer Center. (bvsalud.org)
  • Thirty-six patients (46%) achieved MRD-negative ≥VGPR at day +100 after autoHCT, and 40 patients (51%) did so at best post-transplantation response. (bvsalud.org)
Metastases2
  • The recurrence, which presented with multiple metastases in the bone marrow, occurred 2 years after PBSCT (Figure 1 A). At this time, VAM and HVA had increased to 273.5 and 87.7 μg/mg Cr, respectively. (biomedcentral.com)
  • Two-thirds of neuroblastoma tumours have distant metastases in the bone, bone marrow, lymph nodes, liver or subcutaneous tissue upon diagnosis, whereas lung or central nervous system metastasis are extremely rare. (hospitalpharmacyeurope.com)
Immunotherapy1
  • Background Immunotherapy targeting GD2 is very effective against high-risk neuroblastoma, though administration of anti-GD2 antibodies induces severe and dose-limiting neuropathic pain by binding GD2-expressing sensory neurons. (bmj.com)
Tumor10
  • Suppression of inducible CD4 regulatory cells by MHC class I-restricted human tumor epitope specific TCR engineered multifunctional CD4 T cells. (uchc.edu)
  • Non-Vascularised Ipsilateral Fibular strut - A Modality to Treat Giant cell tumor of lower end radius using Anterior Approach. (jbstjournal.com)
  • The goal of treatment of this tumor at the distal radius is complete removal of the tumor and reconstruction of the bone defect in order to preserve maximum function of the wrist joint. (jbstjournal.com)
  • Juxta-articular giant cell tumors of the lower end radius are common and present a special problem of reconstruction after tumor excision. (jbstjournal.com)
  • Giant cell tumor (GCT) of bone is a benign but locally aggressive tumor with tendency for local recurrence [2]. (jbstjournal.com)
  • We studied 5 consecutive cases of GCT involving the distal radius operated by en-bloc resection of tumor followed by reconstruction with ipsilateral non-vascularized fibular graft with a minimum 1 year follow-up. (jbstjournal.com)
  • Transporters on the plasma membrane of tumor cells are promising molecular "Trojan horses" to deliver drugs and imaging agents into cancer cells. (aspetjournals.org)
  • mIBG enters cancer cells through the norepinephrine transporter (NET) where the radioactive decay of 131 I causes DNA damage, cell death, and tumor necrosis. (aspetjournals.org)
  • Because only a fraction of the cells in a tumor die with each treatment (fractional kill), repeated doses must be administered to continue to reduce the size of the tumor. (worldsbest.rehab)
  • Dosage of chemotherapy can be difficult: If the dose is too low, it will be ineffective against the tumor, whereas, at excessive doses, the toxicity (side-effects) will be intolerable to the person receiving it. (worldsbest.rehab)
Neuroblastoma4
  • The subject was a 2-year-old female with a diagnosis of stage 4 neuroblastoma with unfavorable histology according to the international neuroblastoma pathology classification, non-amplification of MYCN, and primary localization to the left adrenal gland with metastasis to the thoracic vertebrae, pelvis, and bone marrow. (biomedcentral.com)
  • Severe peripheral sensory neuropathy ranged from 2% to 9% in patients with neuroblastoma. (nih.gov)
  • IgA3.0 ch14.18 was evaluated in binding assays and in ADCC and antibody-dependent cellular phagocytosis (ADCP) assays with human, neuroblastoma patient and non-human primate effector cells. (bmj.com)
  • A dose escalation study was performed to determine in vivo efficacy of IgA3.0 ch14.18 in an intraperitoneal mouse model using 9464D-GD2 neuroblastoma cells as well as in a subcutaneous human xenograft model using IMR32 neuroblastoma cells. (bmj.com)
PBSCT2
  • In a PBSCT, stem cells are taken from the bloodstream, a far easier and more commonly used procedure. (lymphoma.ca)
  • In cases of unrelated HCT, PBSC transplantation (PBSCT) still comprises only a very small percentage, which reflects the fact that unrelated PBSCT did not come into use in Japan until 2010. (apbmt.org)
Post-transplantation1
  • Causes of mortality in those patients were severe viral pneumonia, post-transplantation hemophagocytic syndrome and meningeal GVHD refractory to ruxolitinib. (scielo.org)
Disorders2
  • Overview of Plasma Cell Disorders Plasma cell disorders are a diverse group of disorders of unknown etiology characterized by Disproportionate proliferation of a single clone of B cells Presence of a structurally and electrophoretically. (merckmanuals.com)
  • 1992). Since then, hematopoietic stem cells, with their unique ability to differentiate into various blood cell types, have proven to be a revolutionary tool in the treatment of numerous hematological disorders. (revistadehematologia.org.mx)
Blood stem-cell2
Refractory2
  • Hematopoietic Stem Cell Transplantation in Refractory Crohn's Disease: Should It Be Considered? (mdpi.com)
  • However, the GVHD mortality remains high in refractory patients, showing that better therapeutic strategies are needed. (scielo.org)
Efficacy2
  • Antibody- and T-cell-based approaches to targeting of B-cell maturation antigen have shown efficacy. (merckmanuals.com)
  • Understanding the molecular mechanisms governing mIBG transport in cancer and normal cells is a critical step for developing strategies to optimize the efficacy of 131 I-mIBG while minimizing toxicity in normal tissues. (aspetjournals.org)